FDA Clears Philips SmartHeart AI to Streamline Cardiac MR Imaging

The U.S. Food and Drug Administration has cleared SmartHeart AI, a cardiac imaging workflow tool developed by Philips to simplify cardiac magnetic resonance (MR) examinations.

Cardiac MR imaging is considered one of the most technically complex MRI applications because it requires precise coordination of cardiac and respiratory motion to avoid imaging artefacts. SmartHeart AI aims to reduce this complexity by automating 14 standard and advanced cardiac imaging views in under 30 seconds.

Trained on more than 1,200 MR datasets, the system helps reduce operator variability and improves workflow consistency by limiting the need for manual adjustments during scans. Philips says the tool can also reduce the number of patient breath-holds by up to 75%, improving comfort during imaging.

SmartHeart AI integrates with additional tools in Philips’ cardiac MR suite, including CINE FreeBreathing, Cardiac Motion Correction, and CardiacQuant Perfusion, which support improved diagnostic imaging and quantitative assessment of heart function.

09-03-2026